ESHAP regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[etoposide]], [[methylprednisolone|methylprednisolone (Solumedrol)]], high-dose [[cytarabine]] and [[cisplatin]], used to treat relapsed and refractory [[Hodgkin's lymphoma|Hodgkin's]] and [[Non-Hodgkin's lymphoma]]<ref name="pmid8201379">{{cite journal| author=Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA et al.| title=ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. | journal=J Clin Oncol | year= 1994 | volume= 12 | issue= 6 | pages= 1169-76 | pmid=8201379 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8201379 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63377}}</ref> and rituximab added for the treatment of | {{PAGENAME}} refers to a regimen consisting of [[etoposide]], [[methylprednisolone|methylprednisolone (Solumedrol)]], high-dose [[cytarabine]] and [[cisplatin]], used to treat relapsed and refractory [[Hodgkin's lymphoma|Hodgkin's]] and [[Non-Hodgkin's lymphoma]]<ref name="pmid8201379">{{cite journal| author=Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA et al.| title=ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. | journal=J Clin Oncol | year= 1994 | volume= 12 | issue= 6 | pages= 1169-76 | pmid=8201379 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8201379 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63377}}</ref> and rituximab added for the treatment of Diffuse large B-cell lymphoma. <ref name="pmid24751603">{{cite journal| author=Montoro J, Andreola G, Gardellini A, Babic A, Negri M, Frungillo N et al.| title=R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. | journal=Transfus Apher Sci | year= 2014 | volume= 50 | issue= 3 | pages= 411-4 | pmid=24751603 | doi=10.1016/j.transci.2014.03.006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24751603 }} </ref> | ||
==Regimen== | ==Regimen== | ||
Revision as of 15:12, 16 March 2015
|
WikiDoc Resources for ESHAP regimen |
|
Articles |
|---|
|
Most recent articles on ESHAP regimen Most cited articles on ESHAP regimen |
|
Media |
|
Powerpoint slides on ESHAP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ESHAP regimen at Clinical Trials.gov Trial results on ESHAP regimen Clinical Trials on ESHAP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ESHAP regimen NICE Guidance on ESHAP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ESHAP regimen Discussion groups on ESHAP regimen Patient Handouts on ESHAP regimen Directions to Hospitals Treating ESHAP regimen Risk calculators and risk factors for ESHAP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ESHAP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:ESHAP Regimen; Etoposide-Solumedrol-High Dose Ara-C, Platinol Regimen
Overview
ESHAP regimen refers to a regimen consisting of etoposide, methylprednisolone (Solumedrol), high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin's and Non-Hodgkin's lymphoma[1][2] and rituximab added for the treatment of Diffuse large B-cell lymphoma. [3]
Regimen
EEtoposide
SMethylprednisolone (Solumedrol)
HHigh-dose
ACytarabine (Ara-c)
PCisplatin (Platinol)
Indications
- Relapsed and refractory Hodgkin's and Non-Hodgkin's lymphoma[1][4]
References
- ↑ 1.0 1.1 Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA; et al. (1994). "ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study". J Clin Oncol. 12 (6): 1169–76. PMID 8201379.
- ↑ "NCI Thesaurus".
- ↑ Montoro J, Andreola G, Gardellini A, Babic A, Negri M, Frungillo N; et al. (2014). "R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma". Transfus Apher Sci. 50 (3): 411–4. doi:10.1016/j.transci.2014.03.006. PMID 24751603.
- ↑ "NCI Thesaurus".